ReviewThe Journal of allergy and clinical immunology2008
Critical issues in mucosal immunity for HIV-1 vaccine development.
Review in The Journal of allergy and clinical immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Trial
- Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.Journal of virology · 2013Trial
- Trial
- Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.PloS one · 2011Trial
- RecombinantVaccines · 2025Review
- Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity.Nanomedicine (London, England) · 2016Article
- New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections.Journal of sexually transmitted diseases · 2016Review
- Article
- Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.Journal of virology · 2014Article
- Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro.The AAPS journal · 2014Article
- Sexual violence and HIV transmission: summary proceedings of a scientific research planning meeting.American journal of reproductive immunology (New York, N.Y. : 1989) · 2013Article
- Overview of microbicides for the prevention of human immunodeficiency virus.Best practice & research. Clinical obstetrics & gynaecology · 2012Review
- Measurements of immune responses for establishing correlates of vaccine protection against HIV.AIDS research and human retroviruses · 2012Article
- Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice.European journal of immunology · 2012Article
- Article
- Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.PLoS pathogens · 2011Article
- Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates.PloS one · 2011Article
- HIV vaccines: progress to date.Drugs · 2011Review
- A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.PloS one · 2011Article
- Characterization of an effective CTL response against HIV and SIV infections.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Development of a safe and effective vaccine for HIV-1 infection is a critical global priority. However, the nature of host-virus interactions that lead to early immunosuppression and CD4 depletion, HIV-1 diversity, and the inability of the immune system to eliminate the latently infected CD4 pool of cells has to date thwarted successful vaccine development. Moreover, both the initial antibody-inducing vaccine (protein envelope gp120) and cell-mediated vaccine (recombinant adenovirus containing HIV-1 genes) strategies have failed in efficacy trials, and the latter cell-mediated vaccine appeared to have caused enhanced HIV-1 acquisition. Thus basic and translational research to understand why current vaccines have failed and elucidation of new mechanisms of virus control at mucosal surfaces is essential for eventual successful development of a preventive HIV-1 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.